Last reviewed · How we verify
NCT06949462: PEAR
Effectiveness of Large Language Model for Anaesthesia and Procedural Consent
NA trial testing PEAR in Consent Forms in 120 participants. Not yet recruiting.
1 July 2026
Quick facts
| Lead sponsor | Singapore General Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | other |
| Enrollment | 120 |
| Start date | 1 July 2025 |
| Primary completion | 1 July 2026 |
| Estimated completion | 1 July 2026 |
| Sites | 1 location across Singapore |
Drugs / interventions tested
- PEAR
Conditions studied
- Consent Forms — all drugs for Consent Forms →
- Anesthesia — all drugs for Anesthesia →
- Artificial Intelligence (AI) — all drugs for Artificial Intelligence (AI) →
Sponsor
Singapore General Hospital
Who can join
Adults 21 to 99, any sex, with Consent Forms or Anesthesia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patient understanding of anaesthesia risks remains inconsistent due to time constraints, language barriers, and variable clinician communication styles. Traditional verbal consent may not consistently ensure comprehension or reduce preoperative anxiety. PEAR (Patient Education of Anesthesia Risks) is a multilingual, AI-driven chatbot developed to enhance patient education and improve the quality of anaesthesia risk counselling. Study Objective: To compare PEAR's performance in delivering anaesthesia risk consent against the standard face-to-face verbal method.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06949462
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Consent Forms
Currently open trials in the same condition.
- NCT07403084 — Post-market Clinical Follow-up Study of NEMOST V2 · NA · recruiting
Other Singapore General Hospital trials
Trials by the same sponsor.
- NCT07452159 — Diabetes In Asians at Risk in Youth · not yet recruiting
- NCT07527247 — Improving Vaccine Protection for Older Adults · Phase 2 · recruiting
- NCT07533188 — Patient Outcomes Following Kinematic and Functional Alignment in Robotic-Assisted Total Knee Arthroplasty With Randomize · NA · recruiting
- NCT07042061 — Trial of Mobile External Defibrillator for Out-of-hospital Cardiac Arrest in Singapore. · NA · not yet recruiting
- NCT07099040 — Community-based Multi-domain Intervention to Detect and Delay Cognitive Decline in Community-dwelling Older Adults: A Pi · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06949462 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Singapore General Hospital
- Last refreshed: 1 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06949462.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing